Hikma Pharmaceuticals (LON:HIK) Trading Down 0.5% - What's Next?

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) fell 0.5% during trading on Friday . The stock traded as low as GBX 1,919 ($24.46) and last traded at GBX 1,931 ($24.61). 138,066 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 506,818 shares. The stock had previously closed at GBX 1,940 ($24.73).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank raised shares of Hikma Pharmaceuticals to a "buy" rating and upped their price target for the stock from GBX 2,100 ($26.77) to GBX 2,400 ($30.59) in a report on Monday, September 2nd.

Hikma Pharmaceuticals Stock Performance

The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.48. The firm has a market capitalization of £4.28 billion, a price-to-earnings ratio of 2,970.77, a PEG ratio of 2.38 and a beta of 0.41. The stock's 50-day moving average is GBX 1,902.86 and its 200-day moving average is GBX 1,921.10.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.